In abiraterone/prednisone-treated postmenopausal ER+ advanced BC patients neither the analysis of biomarkers in serum, CTCs nor tumor tissue identified a subgroup a patients with significantly improved PFS, although dual expression of AR and ER in baseline CTCs were supposed to have an association with improved PFS (47). Here, AR is linked to breast cancer.